Problems associated with the screening of drugs for possible teratogenic activity.
D015085:2,4,5-Trichlorophenoxyacetic Acid / Q000633:toxicity; D000014:Abnormalities, Drug-Induced / Q000145:classification / Q000453:epidemiology; D000818:Animals; D001241:Aspirin / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005260:Female; D005298:Fertility / Q000187:drug effects; D006330:Heart Defects, Congenital / Q000139:chemically induced; D006343:Heart Septal Defects / Q000139:chemically induced; D007668:Kidney / Q000002:abnormalities; D008098:Litter Size; D051379:Mice; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000378:metabolism; D011247:Pregnancy; D011817:Rabbits; D051381:Rats; D012107:Research Design; D012119:Respiration; D013045:Species Specificity; D013131:Spine / Q000002:abnormalities; D013723:Teratogens; D013792:Thalidomide / Q000633:toxicity; D014116:Toxicology
D004364:Pharmaceutical Preparations; D013723:Teratogens; D013792:Thalidomide; D015085:2,4,5-Trichlorophenoxyacetic Acid; D001241:Aspirin